FINWIRES · TerminalLIVE
FINWIRES

德意志銀行預計,加幣今年對美元將「小幅」上漲,2027年漲幅將更大。

By

-- 德意志銀行預計,今年加元(CAD 或 loonie)兌美元(USD)的漲幅將“溫和”,落後於其他G10貨幣,但預計2027年將出現更大幅度的上漲。 該行指出,加拿大經濟依然「疲軟」——國內生產毛額成長幾乎為零,通膨率也已回落至目標水準附近。 德意志銀行表示,加拿大正處於兩難:一方面是傳統成長動力(人口、房價和出口的強勁成長)的逐漸消退,另一方面是新的成長動力(例如增加資本支出和實現出口市場多元化)的希望。 該行指出,目前的趨勢“令人鼓舞”,加拿大央行上周公布的第一季商業調查(BOS)也出現回升,但這些舉措仍需時間才能見效。專案建置並非一朝一夕之功,尤其是在涉及眾多利害關係人的情況下,而且企業普遍需要被說服重新調整策略並加大投資。 德意志銀行補充道,當前的能源衝擊影響了市場情緒,尤其是對那些本就面臨G10國家中最疲軟勞動力市場狀況的家庭而言。 能源價格上漲至少有助於改善貿易平衡,而金融帳仍呈現股權資金外流被債務資金流入抵銷的局面——儘管加幣的利差相對較低。 德意志銀行認為,定於年中進行的USMCA貿易協定重新談判對加幣構成雙向風險,而退休基金對沖規模從極低水準進一步擴大,長遠來看可能有助於加幣走強。

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Australia

Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set

Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.

$CLS
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP